Department of Radiology, Quanzhou First Hospital, Quanzhou, Fujian, China , hrisheng@126.com
Abstract: (10 Views)
Background: This research attempted to elucidate amide proton transfer (APT) role in combination with relative cerebral blood volume (rCBV) in grading adult diffuse glioma and predicting isocitrate dehydrogenase (IDH) gene mutation status. Materials and Methods: A retrospective analysis was implemented on 70 patients with adult diffuse glioma in our hospital from September 2022 to October 2023. All patients underwent Dynamic Susceptibility Contrast Perfusion Weighted Imaging (DSC-PWI) and APT-weighted magnetic resonance imaging examination. The values of rCBVmax and APTmean in differentiating the classification of glioma and IDH gene mutation status were analyzed. Results: The rCBVmax and APTmean value were reduced in grade II patients than in grade III patients (P<0.01). The AUC of rCBVmax value combined with APTmean value was 0.9330, with a 95% CI of 0.8962-0.9697, which was higher than single rCBVmax value or APTmean value (P<0.001). The rCBVmax value and APTmean were higher in IDH wild-type glioma patients than in IDH mutant-type glioma patients (P<0.01). The AUC of rCBVmax value combined with APTmean value was 0.8808, with a 95% CI of 0.8233-0.9383, which was higher than single rCBVmax value or APTmean value (P<0.001). Conclusion: The combined diagnosis of APT and rCBV can improve the value of differentiating grade I and II glioma as well as IDH genotyping, which is worth of promoting in clinical practice.
Send email to the article author
